|
Mar 18
|
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
|
|
Mar 18
|
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
|
|
Mar 15
|
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
|
|
Mar 15
|
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
|
|
Mar 13
|
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
|
|
Mar 12
|
Fortress Biotech to Participate in 36th Annual ROTH Conference
|
|
Mar 11
|
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
|
|
Mar 11
|
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
|
|
Mar 7
|
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
|
|
Mar 4
|
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
|
|
Feb 2
|
Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
|
|
Jan 11
|
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 11
|
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 11
|
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
|
|
Jan 9
|
Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...
|
|
Dec 29
|
Fortress Biotech Announces Pricing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Dec 13
|
Analysts Expect Breakeven For Fortress Biotech, Inc. (NASDAQ:FBIO) Before Long
|
|
Dec 11
|
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
|
|
Dec 6
|
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
|
|
Dec 6
|
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics
|